Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 21 Nov 2018 Planned End Date changed from 21 Aug 2019 to 31 Dec 2020.
- 21 Nov 2018 Planned primary completion date changed from 21 Aug 2019 to 31 Dec 2020.
- 21 Nov 2018 Status changed from recruiting to active, no longer recruiting.